A series of 7 new human/rat Corticotropin Releasing Hormone (h/r-CRH) analogues were synthesized. The induced alterations include substitution of Phe at position 12 with D-Phe, Leu at positions 14 and 15 with Aib and Met at positions 21 and 38 with Cys(Et) and Cys(Pr). The analogues were tested regarding their binding affinity to the CRH-1 receptor and their activity which is represented by means of percentage of maximum response in comparison to the native molecule. The results indicated that the introduction of Aib, or Cys derivatives although altering the secondary structure of the molecule, did not hinder receptor recognition and binding.
Introduction
Ever since its identification by Vale et al. [1] , Corticotropin Releasing Hormone (CRH) has proven to be a major neuromodulator responsible not only for the secretion of ACTH by the anterior pituitary gland but also for the regulation of the endocrine, autonomic, immunological and behavioral responses to stress [2] [3] [4] . Furthermore, this 41-amino acid neuropeptide displays a plethora of additional roles in either physiological homeostasis or pathogenic manifestations varying from the well-established implication on neuropsychiatric disorders [5, 6] to the yet to be clarified actions on various forms of cardiovascular diseases [7] obesity [8] or gut motility [9] , among others. A series of studies demonstrating the extent and perplexity of the roles and implications of CRH led to the identification of other peptides appearing to possess a similar role [10] [11] [12] [13] .
Both the isolation and characterization of the CRH family receptors has been achieved revealing two receptor subtypes, one of them appearing as three splice variants (CRH-R1, CRH-R2 α , CRH-R2 β , and CRH-R2 γ ). A binding protein (CRH-BP) was also described [14] [15] [16] [17] [18] .The moststudied receptor types are CRH-R1, CRH-R2 α , and CRH-R2 β not only due to their vast distribution but also for their implication in physiological functions or disorders of great importance. CRH-R1 is broadly distributed in the brain and the pituitary gland but also appears in a number of peripheral tissues [19] . It possesses a critical role in mediating the hypophysiotropic action of CRH [20] but furthermore is involved in anxiogenic behaviours, depression and anxiety [21] , anorexia and bulimia, drug seeking and withdrawal, and seizure [22, 23] . CRH-R2 α is mainly a brain receptor whereas CRH-R2 β is largely expressed in the periphery. The role of CRH-R2 is more diverse since it extends from "stress-coping" responses (anxiolysis, hypotension) to gastric emptying, regulation of energy expenditure, anti-inflammatory, and other actions of CRH [24] . However, further and complete understanding of the hormone-receptor interaction on its chemical basis is essential mainly since it can provide a solid basis for the development of CRH analogues with potent therapeutical implications.
Bioinorganic Chemistry and Applications
Two distinct categories of CRH receptor ligands (of either agonistic or antagonistic character) have been developed, namely, peptide and nonpeptide ligands. The latter are unambiguously a large and diverse family but only few of these small molecules entered clinical development and still none of them found its way to the market [25] . The former category is more likely to yield clear information regarding the interaction between the peptide and its receptor.
Towards this goal, extensive SAR studies have been carried out. Single amino acid modification studies identified the key regions of the peptide for agonist/antagonist properties as well as for the receptor binding affinity. Based on these studies, the assignment of the molecule's secondary structure was feasible leading to the establishment of an α-helical structure (showing high amphiphilicity) for CRH-related peptides as the preferred conformation [9] . Notably, the helical nature of the molecule varies from 20% in solution to 80% upon binding [26] .
A hypothesis was that stabilization of the α-helix could affect positively the activity of either agonists or antagonists. Subsequent studies affirmed this conjecture establishing that conformationally restrained analogues present increased potency. In addition, modifications on hydrophilicity/hydrophobicity or acidity/basicity of some residues were crucial in altering the potency of an analogue [26] .
Introduction of D-amino acids leading to stabilization of β-turns, can provide analogues with increased potency but not all residues are susceptible to such an alteration, leading even to the opposite effect. However, the D-Phe 12 substitution has proven to be a favorable one especially combined with other advantageous modifications such as the replacement of Met at positions 21 [26] .
The present study presents the synthesis of 7 new h/r-CRH analogues bearing minor modifications on the key amino acids side chain, regarding their electrochemical nature (Table 1) . Specifically, we discuss the replacement of Leu at positions 14 and 15 with α-Aminoisobutyric acid (Aib), which apart from introducing a bend in the peptide backbone can stabilize the a-helix structure [27, 28] , and also the replacement of Met at positions 21 and 38. The amino acids used for the latter modification are Cysteine(Ethyl) [Cys(Et)], an isoster of Met and Cysteine(Propyl) [Cys(Pr)] that possesses a slightly more hydrophobic side chain than Cys(Et). The analogues were tested regarding their ability to induce the formation of intracellular cAMP in comparison to natural CRH measured by means of luciferase activity. [33] to provide the peptide amide. The side-chain protection used for the Fmoc-protected amino acids was the trityl group (Trt) for His, Asn, and Gln, the tert-butyl group (Bu t ) for Asp, Tyr, Glu, Ser and Thr, the tertbutyloxy-carbonyl group (Boc) for Lys and the 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulphonyl group (Pbf) for Arg. Stepwise synthesis of the peptide analogues was preferred to convergent synthesis due to the lack of Gly or Pro moieties at convenient positions in the amino acid sequence. The amino acids were coupled at three-fold excess using diisopropylcarbodiimide/1-hydroxybenzotriazole (DIC/HOBt) [34, 35] in Dimethylformamide (DMF) and, if necessary, 2-(1H-benzotriazole-1-yil)-1,1,3,3-tetramethyluroniumhexafluorophosphate (TBTU)/HOBt/diisopropyl ethylamine (DIEA) in DMF [36] . After 2 hours coupling time at room temperature, the ninhydrin test [37] was performed to estimate the completeness of the reaction with the exception of coupling on a Pro residue where the Chloranil test was employed to confirm reaction's completion point [38] . Fmoc groups were removed by treatment with 20% piperidine in DMF for 5 minutes followed by a prolonged treatment with the same solution for 20 minutes to ensure complete removal. The final cleavage of the peptide from the solid support together with the removal of the side-chain protecting groups was accomplished by treatment with a solution (15 mL/g peptide resin) of trifluoroacetic acid (TFA)/1,2-ethanedithiol/anisole/triethylsilane/water (94 : 2.5 : 0.5 : 1.5 : 1.5, v/v) for 4 hours at room temperature. The obtained mixture underwent solvent evaporation followed by anhydrous ethyl ether precipitation to yield the final crude peptide.
Experimental
All the products were purified by gel filtration chromatography on Sephadex G-25 (fine) using 25% acetic acid as eluent. Final purification was achieved by preparative high performance liquid chromatography (HPLC, Pharmacia LKB-2250) on reversed-phase support C-18 with a linear gradient from 30 to 85% acetonitrile (0.1% TFA) for 35 minutes at a flow rate 1.5 mL/min and UV detection at 230 and 254 nm. The appropriate fractions were pooled and lyophilized. Analytical HPLC (Pharmacia LKB-2210) equipped with a Nucleosil 100 C 18 column (5 μm particle size; 250×4.6 mm) produced single peaks with at least 98% of the total peptide peak integrals. The solvent system used was the same as that for the semipreparative HPLC. All products gave single spots on thin layer chromatography (TLC, Merck precoated silica gel plates, type G 60 -F 254 ) in the solvent systems: (A) 1-butanol: acetic acid: water (4 : 1: 5, upper phase) and (B) 1-butanol: acetic acid: water: pyridine (15 : 3: 10 : 6). The final characterization of the peptide sequence was phenol red with glutamine, antibiotics, and 10% FCS) to a total volume of 50 mL. The suspension was distributed in 8 plates of 24 wells each, by adding 1 mL per well, and was allowed to pre-incubate for 24 hours. The growth medium was aspirated and replaced with fresh one followed by another preincubation for 24 hours. The cells were then challenged with graded concentrations (10 −6 to 10 −11 M) of the test peptides and incubated for 7 hours at 37
• C. After that, the medium with the added peptides was removed, the cells were washed twice with PBS 1X, 100 μL of lysis buffer 1X per well were added, the plates were left at room temperature for 30 minutes and then stored at −80
• C overnight. The luciferace activity was measured with the use of a luminometer after the addition of 50 μL of lysed cell preparation and 50 μL of bioluminescence medium per well in a 96 well plate luminometer. Table 2 were synthesized either manually or automatically on the Rink Amide MBHA resin or the 2-chlorotritylchloride resin bearing a Rink-Bernatowitz linker as solid support by using standard coupling procedures and Fmoc/Bu t strategy. The overall yield of the syntheses of the CRH analogues was in the range 33-41% (calculated on the amount of linker initially coupled to the resin). Higher yields were obtained using the Rink Amide MBHA as solid support. The synthetic procedure did not present significant complications due to the highly helical nature of the analogues despite the considerable size of the CRH analogues. ESI mass spectrometry confirmed that the purified products were indeed the desired peptides and analytical HPLC revealed a purity of over than 98% for the synthetic analogues.
Results
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Biological Activity.
The results of the biological evaluation regarding the synthesized analogues are set out in Tables  3 and 4 . The IC 50 values (Table 3) Regarding the activity of the analogues which is represented by means of percentage of maximum response compared to that of h/r-CRH (Table 4 ), the only analogue that presents a higher percentage is [D-Phe 12 , Cys(Et) 21 ]CRH (full agonist, 110% response max/CRH). All other analogues are partial agonists and induce a maximum response that varies between 60 and 80 per cent of the maximum response induced by CRH.
Discussion
The design and synthesis of the seven analogues was based on observations and results already mentioned above and likely to yield products with desirable properties. D-Phe 12 substitution was a modification present in all analogues since it brings only a positive contribution to the potency and the activity of the analogue. Substitution of Leu at positions 14 and 15 with Aib was based on studies demonstrating that α-aminoisobutyric acid is a helix-promoter/stabilizer, which increases the helix propensity of a peptide fragment towards, either α-or 3 10 -helix, by restriction of the backbone conformational freedom. Aib, on the other hand, apart from its tendency to form constrained helices, is also known for its ability to bend helical peptides. 15 ]CRH is the best means to clarify the effect of the Aib substitution on the molecule conformation and consequently on its binding to the receptor. All the same, a primary estimation could be that the positions 14 and 15 although important for binding to the receptor might not belong to the region that is responsible for the hormone's action since no alteration is observed on the biological activity for the two analogues.
Cys(Et) and Cys(Pr) are two nonnatural amino acid residues that have already been used in the synthesis of peptides (e.g., Angiotensin II) [40] yielding interesting results. The fact that Cys (S-Et) is an isoster of Met along with the enhanced potency of the analogues with substituted Met 21 or Met 38 were basically taken into account for the design of the analogues. Cys (S-Pr) was used since it bears a side-chain that on one hand possesses the S atom present in Met and on the other hand has a longer aliphatic unit than Met or Cys(Et). Two of the analogues were monosubstituted regarding the Met residues, [D-Phe 12 21 , Cys(Pr) 38 ]CRH, although slightly higher than that of the latter monosubstituted analogue is considerably lower than that of the former one. This could mean that the negative effect of Cys(Pr) 38 is more prominent than the positive one of Cys(Et) 21 . As for the affinity, no safe assumptions can be made until further NMR studies are performed on these molecules.
The results regarding [D-Phe 12 , Cys(Pr) 21 , Cys(Pr) 38 ] CRH indicate that double substitution with Cys(Pr) does not affect the affinity of the molecule to the receptor and decreases only slightly its activity. When the Cys(Pr) residue is applied at position 38 the IC 50 value is negatively affected and the molecule shows a 40% decrease in activity compared to CRH. The reversal of this image with the application of Cys(Pr) 21 could be attributed to a positive effect of this moiety on the molecule but this assumption can be confirmed only by the study of the [D-Phe 12 , Cys(Pr) 21 ]CRH analogue that remains to be performed.
The analogue presenting the lowest IC 50 value is [D-Phe 12 , Cys(Pr) 21 , Cys(Et) 38 ]CRH, indicating a 5-fold increased affinity to the receptor compared to the native hormone and also to the [D-Phe 12 , Cys(Pr) 21 , Cys(Pr) 38 ]CRH. Regarding the two CRH analogues it could be assumed that the difference in affinity is connected with the residue at position 38, where the Cys(Et) substitution appears to be more favorable compared to Cys(Pr) substitution.
Considering all the aforementioned remarks, the conclusions are (i) regarding the introduction of Aib, position 15 is preferable to position 14 since it yielded analogues with higher affinity to the receptor; (ii) although the introduction of Aib modifies the secondary structure and can alter significantly the affinity to the receptor, the Aib containing analogues can still be characterised as partial agonists; (iii) affinity to the receptor and activity do not necessarily coincide and analogues that excel in the one may fall short to the other; (iv) simple or combined modifications with Cys(Et) or Cys(Pr) in position 21 or/and position 38 did not hinder receptor recognition leading, in the most of the cases, to partial agonists with the exception of the analogue [D-Phe 12 , Cys(Et) 21 ]CRH which presents full agonistic activity.
